Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Ending Cash Position : $22.46 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Ending Cash Position?

Paradigm Biopharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2023 was $22.46 Mil.

Paradigm Biopharmaceuticals's quarterly Ending Cash Position declined from Dec. 2022 ($56.63 Mil) to Jun. 2023 ($37.81 Mil) and declined from Jun. 2023 ($37.81 Mil) to Dec. 2023 ($22.46 Mil).

Paradigm Biopharmaceuticals's annual Ending Cash Position declined from Jun. 2021 ($54.31 Mil) to Jun. 2022 ($27.88 Mil) but then increased from Jun. 2022 ($27.88 Mil) to Jun. 2023 ($37.81 Mil).

Paradigm Biopharmaceuticals Ending Cash Position Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Ending Cash Position Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Ending Cash Position

Get a 7-Day Free Trial

50.23

71.72

54.31

27.88

37.81

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial												39.33	27.88	56.63	37.81	22.46

Paradigm Biopharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Paradigm Biopharmaceuticals's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	26.626	+	11.181
	=	37.81

Paradigm Biopharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	37.706	+	-15.249
	=	22.46

Paradigm Biopharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

PAR:Australia

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).